Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cost and Quality Issues in Establishing Hematopoietic Cell Transplant Program in Developing Countries Publisher Pubmed



Hashmi SK1, 6 ; Srivastava A2 ; Rasheed W1 ; Adil S3 ; Wu T4 ; Jagasia M5 ; Nassar A7 ; Hwang WYK8 ; Hamidieh AA9 ; Greinix HT10 ; Pasquini MC11 ; Apperley JF12 ; Aljurf M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
  2. 2. Department of Hematology, CMC, Vellore, India
  3. 3. Department of Oncology, Aga Khan University Hospital, Pakistan
  4. 4. Department of BMT, Hebei Yanda Lu Daopei Hospital, China
  5. 5. Department of Medicine, Vanderbilt University, TN, United States
  6. 6. Department of Internal Medicine, Mayo Clinic, MN, United States
  7. 7. National Research Center, Egypt
  8. 8. Duke-NUS Medical School, Singapore
  9. 9. Tehran University of Medical Sciences, Iran
  10. 10. Medical University of Graz, Austria
  11. 11. Medical College of Wisconsin, WI, United States
  12. 12. Hammersmith Hospital, Imperial College, United Kingdom

Source: Hematology/ Oncology and Stem Cell Therapy Published:2017


Abstract

The hematopoietic cell transplant (HCT) activity has grown significantly over the past two decades in both developing and developed countries. Many challenges arise in establishing new HCT programs in developing countries, due to scarcity of resources and manpower in expertise in HCT. While cost issues can potentially hinder establishment of new HCT programs in certain regions, the focus on quality and value should be included in the general vision of leadership before establishing an HCT program. The main challenge in most developing countries is the lack of trained/qualified personnel, enormous start-up costs for a tertiary care center, and quality maintenance. Herein, we discuss the main challenges from a cost and quality perspective which occur at initiation of a new HCT program. We give real world examples of two developing countries that have recently started new HCT programs despite significant financial constraints. We also portray recommendations from the Worldwide Network of Blood and Marrow Transplantation for levels of requirements for a new HCT program. We hope that this review will serve as a general guide for new transplant program leadership with respect to the concerns of balancing high quality with concurrently lowering costs. © 2017 King Faisal Specialist Hospital & Research Centre